Chondrosarcoma affects men more than women (ratio 1.5:1). It is also known that women have improved survival, compared to men of similar age. This effect diminishes after the age of menopause, suggesting that oestrogen could have a protective effect in chondrosarcoma.
We have awarded our first Ideas Grant focused on chondrosarcoma research, to a collaborative project between the University of Sheffield, the Royal Orthopaedic Hospital in Birmingham and the University of East Anglia.
The team, led by Professor Alison Gartland at the University of Sheffield, aims to answer the question: “Does the hormone oestrogen have a protective effect in chondrosarcoma?”
What are the aims of this research project?
The project will test the effect of oestrogen on human chondrosarcoma cell growth and migration and will investigate the effects of oestrogen on chondrosarcoma tumour growth and progression in a patient-derived xenograft (PDX) model of human chondrosarcoma.
How could this project improve treatment options for chondrosarcoma patients?
This project will provide specific new information on the role of oestrogen in chondrosarcoma progression. In addition, it will provide proof that patient derived chondrosarcoma models can indeed be generated in the UK, to be used by this and other projects studying chondrosarcoma. These results will provide the foundations to fully exploit the oestrogen involvement as a potential new therapeutic target.